Financials in USD. Standardized financial statements.
A compact view of how Harpoon Therapeutics, Inc. turns revenue into operating income and net income.
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|
| Revenue? | $31.91M | $23.65M | $17.44M | $5.78M | $4.75M | $708,000 | $0 |
| Revenue Growth? | +34.9% | +35.6% | +202.0% | +21.6% | +570.9% | 0.0% | 0.0% |
| Cost of Revenue? | $3.10M | $2.65M | $0 | $0 | $0 | $0 | $0 |
| Gross Profit? | $28.82M | $21.01M | $17.44M | $5.78M | $4.75M | $708,000 | $0 |
| Gross Margin? | +90.3% | +88.8% | +100.0% | +100.0% | +100.0% | +100.0% | 0.0% |
| Operating Expenses? | $100.24M | $90.45M | $68.78M | $63.98M | $32.47M | $17.24M | $11.15M |
| Operating Income? | -$68.33M | -$116.75M | -$51.33M | -$58.21M | -$27.72M | -$16.53M | -$11.15M |
| EBITDA? | -$65.97M | -$14.65M | -$49.25M | -$58.21M | -$27.37M | -$16.16M | -$10.95M |
| Income Before Tax | -$67.73M | -$116.72M | -$49.91M | -$55.57M | -$27.37M | -$16.83M | -$11.41M |
| Income Tax Expense | -$594,000 | $49.71M | -$3.53M | -$3.58M | $0 | $0 | $0 |
| Net Income? | -$67.14M | -$166.44M | -$46.38M | -$52.00M | -$27.37M | -$16.83M | -$11.41M |
| EPS? | $-20.24 | $-51.57 | $-18.52 | $-23.91 | $-11.45 | $-17.81 | $-1.21 |
| Diluted EPS? | $-20.24 | $-51.57 | $-18.52 | $-23.91 | $-11.45 | $-17.81 | $-1.21 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality